Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts

Piccini, Paola; Lindvall, Olle; Björklund, Anders; Brundin, Patrik; Hagell, Peter; Ceravolo, Roberto; Oertel, Wolfgang H.; Quinn, Niall; Samuel, Michael; Rehncrona, Stig; Widner, Håkan; Brooks, David J.

doi:10.1002/1531-8249(200011)48:5<689::aid-ana1>3.0.co;2-n

Cited by 233 publications

(107 citation statements)

References 37 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10,25 The magnitude of symptomatic improvement seen over the first 4-6 months in the two placebo-controlled studies matches fairly well the improvement seen in the Lund patients over this time period. However, whereas the Lund patients continued to improve over the subsequent 12-18 months, the patients in the Olanow and Freed studies did not.…”

Section: Figsupporting

confidence: 67%

Cell Therapy for Parkinson’s Disease

Bai

Liu

2011

Comprehensive Biotechnology

View full text Add to dashboard Cite

Section: Figsupporting

confidence: 67%

Cell Therapy for Parkinson’s Disease

Bai

Liu

2011

Comprehensive Biotechnology

View full text Add to dashboard Cite

“…As this was found through the positron emission tomography and histological studies [28][29][30][31][32][33][34][35][36][37]. It has been found that transplantation of the abovementioned tissue can improve movement related problems in PD patients [38]. In a relevant study, it was found that the motor symptoms can improve even for eighteen years after transplantation [39,40].…”

Section: Mesencephalic Tissue Of the Human Fetusmentioning

confidence: 78%

The role of cell based therapy in the treatment of Parkinson’s disease

Habibyar¹

2017

J Syst Integr Neurosci

View full text Add to dashboard Cite

Parkinson's disease (PD) is considered to be the second common neurodegenerative illness after Alzheimer's disease worldwide. It affects 1-2% of the world population. PD is associated with motor symptoms such as bardykinesia, resting tremor, muscle rigidity. Additionally, non-motor symptoms of PD include sleep disturbance, depression and postural instability. These all PD symptoms are attributed to the selective and progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta. A number of pharmacological agents are today available for the treatment of PD. These medications are associated with adverse drug events or lack of efficacy in some patients. Therefore it is required to explore novel methods for the treatment of PD i.e., cell based therapy. A number of cell based therapeutics is tried for the treatment of PD such as embryonic stem cells, induced pluripotent stem cells and somatic stem cells. Although this novel method proved to be effective in PD treatment in animal and clinical studies. But on the other hand it leads to the worsening of the non-motor symptoms. Thus, these studies are not enough, more long term clinical trials are required to proof the efficacy of all aspects of PD through cell based therapy including non-motor symptoms.

show abstract

“…Recently, the graft's functionality has been investigated by Piccini and colleagues, where DA release from the fetal DA neurons was visualized using 11 C-labeled Raclopride [89]. This was followed by a second study where the recovery in motor performance in grafted patients was correlated with reactivation of the frontal cortical areas using H 2 15 O PET, suggesting that functional recover required integration of the graft into host circuitry [108].…”

Section: Applications Of Pet In Neurodegenerative Statesmentioning

confidence: 99%